Company / EPS (Diluted)
Vertex Pharmaceuticals EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$13.89
FY2025
5-year range
$4.51 / $13.89
FY2021-FY2025
Trend
+8.3%
vs FY2024
Sector context
#4 of 204
Health Care
What the data says
Among 204 Health Care companies, Vertex Pharmaceuticals is in the top 2% for eps (diluted). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-3.14 in FY2016 to $13.89 in FY2025.
Based on SEC 10-K filings.
13.89 in FY2025 with a 5-year CAGR of +11.4%. Top quartile in the Health Care sector.
Improved from $9.01 to $13.89 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +10.5%
- 5-Year CAGR
- +11.4%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 204This company $13.89 Sector average -$0.89
▼
+1667.3% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 8.3% year-over-year.
- Ranks #4 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.89 | +8.3% |
| FY2024 | $12.82 | +42.3% |
| FY2023 | $9.01 | -12.4% |
| FY2022 | $10.29 | +128.2% |
| FY2021 | $4.51 | -44.3% |
| FY2020 | $8.09 | +677.9% |
| FY2019 | $1.04 | +326.1% |
| FY2018 | -$0.46 | +80.1% |
| FY2017 | -$2.31 | +26.4% |
| FY2016 | -$3.14 | -58.6% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026